Conference Coverage

Paravalvular Regurgitation Shown Major TAVR Limitation


 

FROM THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF CARDIOLOGY

The PARTNER trial used the SAPIEN Heart Valve System marketed by Edwards Lifesciences. The trial was sponsored by Edwards. Concurrent with Dr. Kodali’s report at the meeting, the results he presented appeared online (N. Engl. J. Med. 2012, March 26;366 [doi:10.1056/NEJMoa1200384]).

The PARTNER trial was sponsored by Edwards Lifesciences. Dr. Cribier said that he is a consultant to Edwards Lifesciences. Dr. Kodali said that he has been a consultant to Edwards Lifesciences, Medtronic, and St. Jude Medical, that he serves on an advisory board for Paieon Medical, and that he owns stock in Thubrikar Aortic Valve. Dr. Guyton said that he had no disclosures.

*Correction, 4/3/2012: An earlier version of this story mischaracterized the findings.

Pages

Recommended Reading

Race and Sex Skew Congenital Heart Surgery Outcomes
MDedge Surgery
Endovascular Repair Effective for Inflammatory AAA
MDedge Surgery
Risk Factors Predict 1-Year Mortality After Elective TEVAR
MDedge Surgery
Societies Release TAVR Credentialing Recommendations
MDedge Surgery
SAPIEN Valve Makers Comment on Proposed TAVR Coverage
MDedge Surgery
Carotid Artery Interventions Break Three Ways
MDedge Surgery
Cardiac Surgical Transfusions Linked to Infection Risk
MDedge Surgery
CoreValve Excels in 'Real-World' Study
MDedge Surgery
Four Common Comorbidities Hike Risk of Late Post-TAVI Death
MDedge Surgery
CORONARY Trial Fails to Show Superiority of Off-Pump CABG
MDedge Surgery